{
    "clinical_study": {
        "@rank": "163283", 
        "arm_group": [
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Experimental", 
                "description": "Placebo Capsules"
            }, 
            {
                "arm_group_label": "Omega 3 intake", 
                "arm_group_type": "Experimental", 
                "description": "Omega 3 intake, morbid obesity"
            }
        ], 
        "brief_summary": {
            "textblock": "Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly\n      obese patients, will improve the inflammatory status? C-reactive protein? Weight?"
        }, 
        "brief_title": "Intake of Omega 3 in Morbidly Obese Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Morbid Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Obesity, Morbid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Intake of EPA and DHA for the management of morbid obesity in capsules\n\n      - Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein,\n      cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of\n      omega 3 capsules and placebo control."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged between 18-65 years,\n\n          -  BMI > 40 kg/m2 (or > 35 kg/m2 with comorbidities),\n\n          -  ambulatory, receiving an oral diet,\n\n          -  with a diagnosis of metabolic syndrome,\n\n          -  and who signed a Term of Free and Informed Consent.\n\n        Exclusion Criteria:\n\n          -  Systemic inflammatory response syndrome,\n\n          -  coma or compromised organ,\n\n          -  fever or infection foci,\n\n          -  cancer with or without chemotherapy and radiotherapy,\n\n          -  radiotherapy, inflammatory diseases of the gastrointestinal tract,\n\n          -  transplant, trauma, surgery or hospital stay in the past 30 days\n\n          -  use of steroids or non-steroid anti-inflammatory or immunomodulators agents or\n             antibiotics,\n\n          -  or those refusing to take part in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113696", 
            "org_study_id": "primary"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega 3 intake", 
                "description": "Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.", 
                "intervention_name": "Omega 3 intake, morbid obesity", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.", 
                "intervention_name": "Placebo Capsules", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "morbid obesity", 
            "BMI at or above 4O kg/m2", 
            "ingestion of omega 3", 
            "inflammatory cytokines", 
            "biochemical factors", 
            "anthropometric factors"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "number_of_arms": "2", 
        "official_title": "The Effect of \u03c9-3 Polyunsaturated Fatty Acids (Eicosapentaenoic Acid and Docosahexanoic Acid) on Morbidly Obese Patients", 
        "overall_contact": {
            "email": "simonebosco@gmail.com", 
            "last_name": "Simone D Bosco, DR.", 
            "phone": "55 (51) 93272527"
        }, 
        "overall_official": {
            "affiliation": "Centro de Obesidade M\u00f3rbida da Pontificia Universidade Cat\u00f3lica do RS", 
            "last_name": "Claudio C Motin, orientador", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "expected from this study verify inflammatory factors such as adipokines, glucose, c reactive protein, lipid profile, triglycerides, and anthropometric data as visceral fat, weight, BMI, in both groups, control and intervention, to see the action of the capsules of omega 3.patient may withdraw any time from ingestion of capsules, and the same will be provided by the laboratory Vitamed, which is regularized with the supervisory bodies and food security of Brazil", 
            "measure": "Decrease of  inflammatory levels on blood", 
            "safety_issue": "Yes", 
            "time_frame": "08 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113696"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The weight will be measured before and after the intake of omega 3.", 
            "measure": "Decrease of weight", 
            "safety_issue": "Yes", 
            "time_frame": "08 weeks"
        }, 
        "source": "Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}